Herein, we conducted a single-arm phase 2 clinical study to explore the efficacy and safety of pyrotinib combined with apatinib in metastatic NSCLC patients harboring HER2 mutations or amplification. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.